CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Lignende værker

• SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen
  af: Moyer, Ann M, et al.
  Udgivet: (2011)
• A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
  af: Dubsky, P., et al.
  Udgivet: (2020)
• Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
  af: Bartsch, Rupert, et al.
  Udgivet: (2021)
• The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
  af: Fitzal, F, et al.
  Udgivet: (2015)
• Everolimus in Postmenopausal, Hormone Receptor-Positive Advanced Breast Cancer: Summary and Results of an Austrian Expert Panel Discussion
  af: Gnant, Michael, et al.
  Udgivet: (2013)